Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomized trial

Journal of Clinical Psychopharmacology

Volumn 25, Issue 5, 2005, Pages 471-475

  Rossini, David ^a   Serretti, Alessandro ^a   Franchini, Linda ^a   Mandelli, Laura ^a   Smeraldi, Enrico ^a   De Ronchi, Diana ^b   Zanardi, Raffaella ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGED; AGITATION; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOMNOLENCE; STOMACH DISEASE;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SERTRALINE;

EID: 25444532855     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000177548.28961.e7     Document Type: Article

References (46)

1. Palsson S, Skoog I. The epidemiology of affective disorders in the elderly: a review. Int Clin Psychopharmacol. 1997;12(suppl 2):3-13.
2. Ernst C, Angst J. Depression in old age: is there a real decrease in prevalence? A review. Eur Arch Psychiatry Clin Neurosci. 1995;245:272-287.
3. Katona CLE. Depression in Old Age. New York, NY: Wiley and Sons; 1994.
4. Katz IR, Streim J, Parmeles P. Prevention of depression, recurrence and complication in late life. Prev Med. 1994;23:743-750.
5. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life. Consensus statement update. J Am Med Assoc. 1997;278:1186-1190.
6. Reynolds CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent depression: a post hoc comparison of elderly ('young old') and midlife patients. Am J Psychiatry. 1996;153:1288-1292.
7. Girling DM, Huppert FA, Brayne C, et al. Depressive symptoms in the very elderly: their prevalence and significance. Int J Geriatr Psychiatry. 1995;10:497-504.
8. Skoog I, Nilsson L, Landahl S, et al. Mental disorders and the use of psychotropic drugs in an 85-year-old urban population. Int Psychogeriatr. 1993;5:33-48.
9. Fichter MM, Witzke W, Leibl K, et al. Psychotropic drug use in a representative community sample: the Upper Bavarian study. Acta Psychiatr Scand. 1989;80:68-77.
10. Magni G, Schifano F, Pastorello M, et al. Use of psychotropic drugs in general medical geriatric inpatients: relationship with various parameters of psychological distress. Neuropsychobiology. 1986;16:181-185.
11. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA. 1997;277:1618-1623.
12. Unutzer J, Patrick DL, Marmon T, et al. Depressive symptoms and mortality in a prospective study of 2,558 older adults. Am J Geriatr Psychiatry. 2002;10:521-530.
13. Bruce ML, Ten Have TR, Reynolds CF 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA. 2004;291:1081-1091.
14. Lyness JM. Treatment of depressive conditions in later life: real-world light for dark (or dim) tunnels. JAMA. 2004;291:1626-1628.
15. Katona CL. New antidepressants in elderly patients. In: Levy R, Howard R, Burns A, eds. Treatment and Care in Old Age Psychiatry. Petersfield, UK: Wrightson Biochemical Publishing Ltd; 1993:157-168.
16. Anstey K, Brodaty H. Antidepressants and the elderly: double-blind trials 1987-1992. Int J Geriatr Psychiatry. 1995;10:165-179.
17. Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late-life depression: a meta-analysis. J Affect Disord. 1997;46:191-217.
18. Sacchetti E, Conte G, Guarneri L. Are SSRI antidepressants a clinically homogeneous class of compounds? Lancet. 1994;344(8915):126-127.
19. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry. 2003;160:1277-1285.
20. Sheikh JI, Cassidy EL, Doraiswamy PM, et al. Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc. 2004;52:86-92.
21. Oslin DW, Streim JE, Katz IR, et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am J Geriatr Psychiatry. 2000;8:141-149.
22. Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in later life. Am J Psychiatry. 2000;157:729-736.
23. Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry. 1999;7:221-227.
24. Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry. 2000:559-568.
25. Trappler B, Cohen CI. Use of SSRIs in "very old" depressed nursing home residents. Am J Geriatr Psychiatry. 1998:83-89.
26. De Wilde JE, Doogan DP. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord. 1982;4:249-259.
27. Gatti F, Bellini L, Gasperini M, et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry. 1996;153:414-416.
28. Zanardi R, Franchini L, Gasperini M, et al. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol. 1998;18:441-446.
29. Zohar J, Keegstra H, Barrelet L. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol. 2003;18:113-119.
30. Zanardi R, Cusin C, Rossini D, et al. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression. J Clin Psychopharmacol. 2003;23:535-539.
31. Leckman JF, Sholomskas D, Thompson WD, et al. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry. 1982;39:879-883.
32. Folstein MS, Folstein SE, McHugh PR. "Mini-Mental State" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
33. Folstein MS, Folstein SE, McHugh PR. Mini-Mental State Exam (MMSE). In: APA, ed. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:422-427.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
35. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM). 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222.
36. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
37. Statistica 4.5, Windows version. Tulsa, Okla: StatSoft Inc; 1993.
38. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol. 1995;9(suppl 4):33-40.
39. Montgomery SA. Efficacy and safety of serotonin reuptake inhibitors in treating depression in elderly patients. Int Clin Psychopharmacol. 1998;13(suppl 5):49-54.
40. Martin AJ, Tebbs VM, Ashford JJ. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica. 1987;5:40-49.
41. Stollmaier W, Cimander KF, Wagner W. Efficacy and tolerance of fluvoxamine in depressives syndromes in the practice. The result of a multicentred study on 2296 patients. Nervenheilkunde. 1989;8:247-252.
42. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998;34:281-302.
43. Schumacher M, Akwa Y, Guennoun R, et al. Steroid synthesis and metabolism in the nervous system: trophic and protective effects. J Neurocytol. 2000;29:307-326.
44. Urani A, Romieu P, Roman FJ, et al. Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice. Behav Brain Res. 2002;134:239-247.
45. Conwell Y, Duberstein PR, Herrmann JH, et al. Relationship of age and Axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry. 1996;153:1001-1008.
46. Winokur G, Coryell W, Keller M, et al. A family study of manic-depressive (bipolar I) disease. Is it a distinct illness separable from primary unipolar depression? Arch Gen Psychiatry. 1995;52:367-373.